Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary
14/05/2025 13:11
Foghorn Therapeutics Inc. FHTX.OQ reported a quarterly adjusted loss of 30 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of six analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -55 cents to -24 cents per share. Revenue rose 17.9% to $5.95 million from a year ago; analysts expected $5.82 million. Foghorn Therapeutics Inc.'s reported EPS for the quarter was a loss of 30 cents. The company reported a quarterly loss of $18.83 million. Foghorn Therapeutics Inc. shares had risen by 18.6% this quarter and lost 8.3% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 8.3% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $10.00 This summary was machine generated from LSEG data May 14 at 12:11 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.34 | -0.30 | Beat |
| Dec. 31 2024 | -0.33 | -0.30 | Beat |
| Sep. 30 2024 | -0.44 | -0.31 | Beat |
| Jun. 30 2024 | -0.65 | -0.45 | Beat |